Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COYANASDAQ:IKNANASDAQ:MEIPNASDAQ:MGTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOYACoya Therapeutics$5.45-10.7%$6.48$4.75▼$10.24$91.15M0.4970,337 shs126,493 shsIKNAIkena Oncology$1.13-5.8%$1.39$1.09▼$1.94$54.53M0.48180,700 shs144,816 shsMEIPMEI Pharma$2.00-6.1%$2.52$1.90▼$4.10$13.33M0.7645,422 shs42,148 shsMGTAMagenta Therapeutics$0.70-7.7%$0.53$0.32▼$2.07$42.44M2.12848,835 shs376,000 shs7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOYACoya Therapeutics0.00%-16.92%-13.35%-10.80%-45.01%IKNAIkena Oncology0.00%-14.39%-20.98%-33.14%-15.36%MEIPMEI Pharma0.00%-14.89%-17.70%-25.37%-50.62%MGTAMagenta Therapeutics0.00%0.00%0.00%0.00%0.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOYACoya Therapeutics1.8507 of 5 stars3.53.00.00.02.70.80.0IKNAIkena Oncology1.9828 of 5 stars3.33.00.00.00.61.71.3MEIPMEI Pharma3.6955 of 5 stars3.05.00.04.20.00.81.3MGTAMagenta TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOYACoya Therapeutics 3.00Buy$17.00211.93% UpsideIKNAIkena Oncology 2.50Moderate Buy$3.00165.49% UpsideMEIPMEI Pharma 2.00Hold$7.00250.00% UpsideMGTAMagenta Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MEIP, MGTA, COYA, and IKNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/20/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/18/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/10/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.002/6/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.002/6/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.001/21/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 4/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOYACoya Therapeutics$3.55M25.65N/AN/A$2.47 per share2.21IKNAIkena Oncology$659K82.75N/AN/A$3.52 per share0.32MEIPMEI Pharma$65.30M0.20$4.55 per share0.44$3.32 per share0.60MGTAMagenta TherapeuticsN/AN/AN/AN/A$1.23 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOYACoya Therapeutics-$7.99M-$0.98N/AN/AN/AN/A-31.63%-27.76%5/8/2025 (Estimated)IKNAIkena Oncology-$68.17M-$1.01N/AN/AN/AN/A-36.88%-33.08%5/12/2025 (Estimated)MEIPMEI Pharma$17.78M-$5.73N/AN/AN/AN/A-84.92%-67.53%5/8/2025 (Estimated)MGTAMagenta Therapeutics-$76.46MN/A0.00∞N/AN/A-70.88%-57.27%N/ALatest MEIP, MGTA, COYA, and IKNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2025Q4 2024COYACoya Therapeutics-$0.32-$0.18+$0.14-$0.18$0.10 million$0.20 million3/11/2025Q4 2024IKNAIkena Oncology-$0.23-$0.18+$0.05-$0.19N/AN/A2/12/2025Q2 2025MEIPMEI PharmaN/A-$0.48N/A-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOYACoya TherapeuticsN/AN/AN/AN/AN/AIKNAIkena OncologyN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/AMGTAMagenta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOYACoya TherapeuticsN/A15.3115.31IKNAIkena OncologyN/A15.3215.32MEIPMEI PharmaN/A10.6610.66MGTAMagenta TherapeuticsN/A19.4919.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOYACoya Therapeutics39.75%IKNAIkena Oncology75.00%MEIPMEI Pharma52.38%MGTAMagenta Therapeutics47.53%Insider OwnershipCompanyInsider OwnershipCOYACoya Therapeutics12.00%IKNAIkena Oncology5.94%MEIPMEI Pharma3.12%MGTAMagenta Therapeutics15.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOYACoya Therapeutics616.73 million14.70 millionNot OptionableIKNAIkena Oncology7048.26 million45.39 millionNot OptionableMEIPMEI Pharma1006.66 million6.46 millionOptionableMGTAMagenta Therapeutics6760.67 million51.46 millionNot OptionableMEIP, MGTA, COYA, and IKNA HeadlinesRecent News About These CompaniesMagenta Token Pre-Sale Now Live: Pioneering a New Era in the MagentaVerse EcosystemNovember 15, 2024 | markets.businessinsider.comMagenta Project: Sam Davies, Pip Hare, and Mariana Lobato share their pathwaysNovember 7, 2024 | sail-world.comMagenta Mobility’s FY24 revenue rises three fold, losses widen by 17.1%November 7, 2024 | yourstory.comFanfulla - Magenta head to head game preview and predictionNovember 5, 2024 | afootballreport.comMagenta Hotels makes first Northern acquisitionOctober 28, 2024 | placenorthwest.co.ukVIRAL | Chattisgarh Man's Desi Recreation Of Magenta Riddim Impresses DJ Snake, Netizens ReactOctober 20, 2024 | republicworld.comCasatese - Magenta head to head game preview and predictionOctober 19, 2024 | afootballreport.comOculi Launches Early Access Evaluation Program with Magenta and Burgundy PlatformsOctober 15, 2024 | 01net.itMagenta Living and Seddon team up to help apprentices using Widnes-based developmentOctober 11, 2024 | msn.comMagenta Living and Bolton-based Seddon Housing Partnerships team up to help apprenticesOctober 9, 2024 | msn.comMagenta Mobility expands its fleet to over 2,000 EVsOctober 4, 2024 | electrive.comMagenta Associates becomes employee ownedOctober 1, 2024 | workplaceinsight.netMagenta Mobility Achieves Major Milestone With Over 2,000 Electric Vehicles In IndiaSeptember 28, 2024 | drivespark.comMagenta sharing gas safety advice at pop-ups this weekSeptember 11, 2024 | msn.comChhattisgarh DJ’s desi twist to ‘Magenta Riddim’ impresses DJ Snake, viral video stuns the internetSeptember 2, 2024 | indianexpress.comDelhi Metro Phase-IV: Safety nod in, Magenta Line extension may open next monthAugust 30, 2024 | msn.comLive in Studio B, Wednesday at 11am: Magenta SunshineAugust 26, 2024 | wncw.orgMagenta Buyer LLC Raises $400 Million of New CapitalAugust 15, 2024 | finance.yahoo.comPuffin to publish second picture book from Zadie Smith, Nick Laird and Magenta FoxAugust 9, 2024 | thebookseller.comMagenta Security launches mental health support programmeJuly 30, 2024 | sourcesecurity.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMEIP, MGTA, COYA, and IKNA Company DescriptionsCoya Therapeutics NASDAQ:COYA$5.45 -0.65 (-10.66%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$5.81 +0.36 (+6.68%) As of 04/4/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Ikena Oncology NASDAQ:IKNA$1.12 -0.08 (-6.75%) As of 04/4/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.MEI Pharma NASDAQ:MEIP$2.00 -0.13 (-6.10%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$2.01 +0.01 (+0.50%) As of 04/4/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Magenta Therapeutics NASDAQ:MGTAMagenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/31 - 04/04 Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential? Conagra Stock Could Thrive as Tariffs Hit Other Sectors Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Advance Auto Parts Stock: A Classic Rebound Play in the Making Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
